Search Results for “HIV” – Page 11 – media

Winner Medical acquires GRI for approximately $120 million

On September 23rd, Steady Medical officially announced the successful acquisition of 75.2% equity in Global Resources International, Inc. (GRI) for approximately $120 million (approximately RMB 840 million) in cash. The first international controlling stake acquisition project of Steady Medical has landed, and low value consumables leader Whale Swallows Global Medical Consumables Giant GRI has opened up a new growth point for Steady Medical overseas. Borrowing a ship to set sail, entering a new stage of global production Founded in 1991, Steady Medical achieved coordinated development in the medical and consumer sectors through two major brands, “Winner Steady Medical” and “Purcotton Era”. On September 17, 2020, Steady Medical officially listed on the ChiNext board. Over the years, Steady Medical has continuously innovated and expanded its industry boundaries, covering multiple fields such as healthcare, personal care, home care, maternal and child care, and home textiles and apparel. Its products have obtained EU ...
- Source: drugdu
- 83
- September 27, 2024
Jacobs’ Pan-KRAS inhibitor approved for clinical trial in the US

September 23, 2024 – The clinical trial application (IND) for Pan-KRAS inhibitor JAB-23E73 independently developed by JACOBIO was approved in the United States, and a Phase I/IIa clinical trial for advanced solid tumors will be conducted in the United States. The IND application for China has been submitted, and clinical trials will be conducted in China simultaneously after approval. KRAS is widely present in a variety of tumor mutations. 23%-25% of cancer patients have KRAS mutations. About 2.7 million new tumor patients with KRAS-related mutations each year are expected to benefit from Pan-KRAS inhibitors. JAB-23E73 can inhibit both active and inactive KRAS, and has no significant inhibition on HRAS and NRAS. As an oral KRAS inhibitor, JAB-23E73’s preclinical data showed good pharmacokinetic properties. JACOBIO is committed to providing patients with breakthrough treatment options. The company’s research projects are based on the six major tumor signaling pathways of KRAS, tumor immunity, ...
- Source: drugdu
- 73
- September 27, 2024
2 injections for 1 year, a preview of conquering AIDS

Since June 2024, all scholars around the world who care about AIDS prevention have focused their attention on Gilead’s antiviral drug lenacapavir. At that time, Gilead announced the latest data of the PURPOSE 1 trial conducted by lenacapavir, and the results showed that: in the case of head-to-head daily oral PrEP drugs, lenacapavir achieved 0 infection with 2 injections per year. This means that in the case of unfavorable vaccine development, lenacapavir is expected to replace the preventive effect of the vaccine with its ultra-persistent prevention characteristics. Of course, is the result of the PURPOSE1 trial accidental or inevitable? No one can give an answer. But in September, Gilead continued to provide PURPOSE 2 trial data, indicating to the outside world that the possibility of inevitability is greater. The results showed that 99.9% of the participants in the Lenacapavir group were not infected with HIV, and the risk of infection ...
- Source: drugdu
- 72
- September 27, 2024
Bausch&Lomb is in a crisis of being sold

Recently, according to the Financial Times, Bausch Lomb, the world’s second-largest ophthalmic giant, is seeking to sell itself and completely spin off from its parent company, Bausch Health. In recent years, under the implementation of merger and acquisition strategies, Doctoral Health has developed its business pipeline comprehensively. However, due to being trapped in a huge debt crisis, it had to reduce its burden and slim down. Bausch&Lomb is one of the targets of its sale and spin off this time. Mergers and acquisitions are both successful and unsuccessful Bausch&Lomb was founded in New York, USA in 1853 and was listed on both the New York Stock Exchange and the Toronto Stock Exchange in 2022. It has a development history of nearly 170 years. At first, Bausch&Lomb was just a small eyewear store, but over the years, it has become one of the world-renowned eye care companies. From the perspective of ...
- Source: drugdu
- 83
- September 26, 2024
Ocuvision nails first generic anti-allergic eye drop

Last week (September 9 to September 15), a total of 58 varieties passed/were deemed to have passed the consistency evaluation. During the same period, 123 varieties applied for consistency evaluation. According to the official website of NMPA, Suzhou Ocuvision Biotechnology Co., Ltd. (hereinafter referred to as “Ocuvision”)’s cetirizine hydrochloride eye drops obtained a marketing approval on September 10. The drug is indicated for the treatment of itchy eyes associated with allergic conjunctivitis and is suitable for people aged 2 years and above. Allergic conjunctivitis is an allergic disease of the eye that occurs more frequently in spring and autumn. The disease is mainly manifested by itchy eyes, accompanied by red and swollen eyelids, congestion and edema of the conjunctiva (white eyeballs), increased tears or white secretions, and some patients also have symptoms such as nasal congestion, itchy nose, clear runny nose, and sneezing. Cetirizine hydrochloride eye drops are one of ...
- Source: drugdu
- 85
- September 26, 2024
Personnel changes in core positions at Medtronic

Recently, Medtronic, the global leader in medical devices, announced that Jorie Soskin has been appointed as the new Vice President and General Manager of TAVR and Congenital Heart Disease businesses. According to data, Jorie Soskin is a seasoned veteran of Medtronic. Since the beginning of this year, multiple personnel changes have been reported at Medtronic. As a giant in the healthcare industry, every decision made by Medtronic may have a profound impact on the entire industry. The personnel changes in core positions also mean a new leadership style and strategic direction. 15 year veteran, helping the high-quality development of TAVR field As mentioned earlier, Jorie Soskin, the newly appointed Vice President and General Manager of TAVR and Congenital Heart Disease Business, is a seasoned veteran of Medtronic, currently residing in Minneapolis, Minnesota, USA. She holds a Bachelor of Arts degree in International Asian Studies from Boston College and has also ...
- Source: drugdu
- 86
- September 25, 2024
Wealth myth” of GLP-1

Recently, the Lasker Award, an important award in the field of biomedicine known as the “vane” of the Nobel Prize, was announced. Among them, the “Clinical Medical Research Award” was awarded to Joel Habener (Massachusetts General Hospital), Lotte Bjerre Knudsen (Novo Nordisk) ) and Svetlana Mojsov (Rockefeller University). The reason for the award is that they discovered and developed GLP-1-based drugs, which revolutionized the treatment of obesity. GLP-1, glucagon-like peptide-1, is a peptide hormone encoded by the human glucagon gene and secreted by intestinal L cells. It can promote the synthesis and secretion of insulin and suppress appetite. Delaying the emptying of gastric contents, etc. Representative products include Novo Nordisk’s semaglutide and Eli Lilly’s tilpotide. It is worth mentioning that the research on GLP-1 has not only received attention from academic awards, but also brought “vast wealth” to companies in the industrial chain due to the huge market demand. The ...
- Source: drugdu
- 94
- September 25, 2024
Edward Life Sciences launches global business layoffs

After Edward Life Sciences (hereinafter referred to as Edward) sold its intensive care business to Becton DickinsonMedical for $4.2 billion, a major global layoff has begun. Approximately 3% of employees will be affected by this layoff, and according to proportional calculations, about 540 employees will be laid off. Edward CEO Bernard Zovighian stated that employees affected by the global layoffs have received notice today that some employees may temporarily stay to assist with the transformation of the intensive care business, while others may find other jobs within the company. 30.4 billion yuan sale, 4500 employees join Becton Dickinson Edward is deeply engaged in the fields of global structural heart disease, intensive care, and surgical monitoring. Currently, he has multiple advanced products such as heart valves, cardiac intervention therapy equipment, cardiac monitoring equipment, and surgical tools. Among them, with the “world’s first successfully implanted artificial mitral valve”, Edward firmly occupies the ...
- Source: drugdu
- 80
- September 24, 2024
Lilly expanded its autoimmune disease product layout

As one of the blue oceans in the field of autoimmune diseases , inflammatory bowel disease (IBD) treatment drugs are sought after and deployed by many multinational pharmaceutical companies. Recently, Eli Lilly acquired Morphic for US$3.2 billion and obtained its core pipeline α4β7 integrin inhibitor MORF-057, further expanding its influence in the field of gastrointestinal diseases. In addition to Eli Lilly, pharmaceutical giants including AbbVie, AstraZeneca, and Merck have laid out IBD treatment drugs and carried out related mergers and acquisitions. Behind the frequent actions, why do multinational pharmaceutical companies favor IBD treatment drugs so much? The dilemma of traditional treatment IBD is a chronic inflammatory bowel disease that mainly affects the digestive system. Its symptoms include severe diarrhea, frequent abdominal pain, blood in the stool, weight loss, and severe cancer. IBD mainly includes two types: ulcerative colitis (UC) and Crohn’s disease (CD). The two IBDs have both overlaps and ...
- Source: drugdu
- 81
- September 24, 2024
AstraZeneca’s “Class 1 Anti-heart Failure Chemical Drug” has applied for clinical trials in China

On September 14, according to the official website of CDE, AstraZeneca’s clinical trial application for the Class 1.1 chemical drug AZD5462 tablets was accepted. According to public information, the drug is a relaxin RXFP1 receptor agonist. Relaxin, as an agonist of the relaxin 1 receptor (RXFP1), produces unique and diverse biological effects, including pulmonary and systemic vasodilation, tissue remodeling/fibrosis reversal, and reduced inflammation, and therefore also has potential in cardiopulmonary diseases. significant curative effect. In addition, this substance is also known as the “pregnancy hormone” and is regulated during pregnancy to help the expectant mother’s cardiovascular system meet the increased demands of the developing fetus and remodel tissue and musculoskeletal structure. . AZD5462 is a relaxin RXFP1 receptor agonist developed by AstraZeneca. Preclinical studies on monkey models of heart failure with reduced ejection fraction (HFrEF) showed that cardiac systolic function was improved after 8 weeks of treatment. There was no ...
- Source: drugdu
- 84
- September 23, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.